MAPK4 and Miyoshi myopathy: These previous studies disclose the oncogenic role of miR-767 in several human cancers, whereas in MM, the function of miR-767 still lacks investigation, and only two studies have been disclosed: the first study observed that miR-767-5p was upregulated in both tissue (two folds) and plasma samples (four folds) from MM patients compared to normal control, and it promotes MM cells (H929 and MM.1S) progression via regulating MAPK4 pathway [30]; the second study observed that miR-767-5p was overexpression in extramedullary relapse MM samples compared to non-extramedullary relapse MM samples [31].